March 2021
Medical benefit specialty drug prior authorization list changing in April for most members
Starting in April 2021, we’re adding prior authorization requirements for some drugs covered under the medical benefit. Providers must request prior authorization through AIM Specialty Health®.
For dates of service on or after April 15, 2021, the following drug will require prior authorization for UAW Retiree Medical Benefits Trust PPO non-Medicare members:
- Kanjinti™ (trastuzumab‑anns), HCPCS code Q5117
For dates of service on or after April 22, 2021, the following drugs will require prior authorization for Blue Cross Blue Shield of Michigan commercial fully insured members and for Blue Care Network commercial, Medicare Plus Blue℠ and BCN Advantage℠ members:
- Danyelza® (naxitamab‑gqgk), HCPCS codes J3490, J3590, J9999, C9399
- Margenza™ (margetuximab‑cmkb), HCPCS codes J3490, J3590, J9999, C9399
These requirements don’t apply to members of the Blue Cross and Blue Shield Federal Employee Program® and MESSA.
Submit authorization requests to AIM through the AIM provider portal** or by calling the AIM Contact Center at 1‑844‑377‑1278.
For information about registering for and accessing the AIM ProviderPortal, see the Frequently Asked Questions page** on the AIM website.
More about the authorization requirements
Authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.
For more information on requirements related to drugs covered under the medical benefit, see:
We’ll update these lists to reflect these changes prior to the effective dates.
**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.
|